Drug intelligence / Profile preview

PF-05297909

Development stage: Phase 1
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

PF-05297909 is an orally administered small molecule drug that was developed by Pfizer for the treatment of Alzheimer's disease. It functions as a beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor and amyloid precursor protein (APP) modulator, targeting the reduction of beta-amyloid production implicated in Alzheimer's pathology. The drug reached phase 1 clinical trials but development was discontinued after completion of these early studies. Its precise mechanism of action remains incompletely defined in public sources, but it is classified among antidementia agents and BACE1 inhibitors.

Targets

BACE1 (Beta-site APP-cleaving enzyme 1)Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on PF-05297909.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-05297909.

Explore the full profile